UL Solutions CEO Jennifer Scanlon sells $937,903 of common stock.

UL Solutions CEO Jennifer F. Scanlon sold 12,500 shares for a total of $937,903 on November 2 under a Rule 10b5-1 plan adopted in December 2025; she retains 114,224 directly held shares and beneficially owns another 89,285 through a family trust. Separately, Q3 2026 adjusted diluted EPS of $0.62 exceeded the $0.45 analyst estimate, while revenue was $823 million, organic growth was 7.0%, and adjusted EBITDA margin reached a quarterly record 28.6%. Shares were up 5.7% over the past week but down 6.4% over the past year.

Analysis

The insider sale is a weak standalone signal: it was pre-scheduled, and the disclosed direct and trust holdings remain substantial relative to the shares sold. It should not outweigh operating evidence unless additional discretionary sales emerge. The more relevant question is whether the recent earnings strength can persist: faster organic growth alongside a record quarterly margin raises the bar for future execution, but one quarter does not establish a durable margin step-up. Over the next 1–3 months, watch organic growth, margin commentary, and whether guidance or estimates move to reflect the stronger result. Over 6–18 months, sustained demand for testing and certification could support operating leverage; a slowdown in client product launches or discretionary compliance projects could reverse it. Intertek, Bureau Veritas, and SGS are useful competitive read-throughs, but relative performance should be checked against comparable business mix and currency exposure. The contrarian point is that the planned sale may attract more attention than it deserves, while investors may be extrapolating a single quarter’s margin peak. The thesis weakens if organic growth decelerates or margins retreat without a clear temporary explanation.

Key Decisions for Investors

• No trade on the insider transaction alone. Treat it as low-information while the sale remains consistent with the existing plan; reassess if subsequent filings show repeated or materially larger discretionary selling.
• For investors seeking exposure, consider ULS on a pullback or after another report confirms organic growth and margin durability rather than chasing the recent rally. Verify valuation and updated estimates first; the supplied data do not establish a fair-value range.
• Track the next results and guidance for organic growth, adjusted EBITDA margin, and evidence of demand breadth. A clear deceleration in growth or sustained margin giveback would falsify the near-term operating-momentum thesis.
• Use Intertek, Bureau Veritas, and SGS as peer checks, not automatic hedges: compare growth and margins on a like-for-like basis before expressing a relative-value position.